Arcus Biosciences sells 1.01M shares to Gilead at $19.26 per share under amended purchase agreement

Arcus Biosciences, Inc.

Gilead to purchase 1,010,000 shares of Arcus common stock at $19.26 per share.
Agreement amends 2021 SPA; Gilead retains option to buy up to 35% of outstanding shares until July 2025.
Shares sold in unregistered transaction under Section 4(a)(2) to accredited investor Gilead.
Closing subject to customary conditions.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Arcus Biosciences, Inc. amended Second Amended and Restated Common Stock Purchase Agreement with Gilead Sciences, Inc. (effective 2023-06-27).

Action: amendment
Agreement: equity purchase
Counterparty: Gilead Sciences, Inc.
Effective: 2023-06-27

Exact text from the filing

On June 27, 2023, Arcus Biosciences, Inc. (“Arcus”) and Gilead Sciences, Inc. (“Gilead”) entered into a Second Amended and Restated Common Stock Purchase Agreement (the “A&R Purchase Agreement”), which amends and restates in its entirety the Amended & Restated Common Stock Purchase Agreement entered into between Arcus and Gilead on January 31, 2021 (the “2021 SPA”).

View on SEC.gov

Browse all material agreements →

Arcus Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-030273

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.